Flufenamic acid in rheumatoid arthritis.

Rajan, K. T.; Hill, Alan; Barr, Alasdair M.; Whitwell, E

doi:10.1136/ard.26.1.43

Cited by 15 publications

(8 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the effective concentration is about 0.25–1.5 mmol according to previous studies, which is far higher than the effective concentration of FFA. As the representative of fenamic acids, FFA is approved by US Food and Drug Administration (FDA) to treat several diseases in the clinic, such as rheumatic arthritis [36, 37]. FFA is inexpensive and can be obtained easily.…”

Section: Discussionmentioning

confidence: 99%

Low concentration flufenamic acid enhances osteogenic differentiation of mesenchymal stem cells and suppresses bone loss by inhibition of the NF-κB signaling pathway

Liu

Líu

et al. 2019

Stem Cell Res Ther

View full text Add to dashboard Cite

Background As the representative of fenamic acids, an important group of NSAIDs, flufenamic acid (FFA) has been used for anti-inflammation and analgesia in the clinic. Recently, researches have focused on the role of some members of NSAIDs in promoting osteogenesis. However, little attention has been paid to the subgroup of fenamic acids, and it remains unclear whether FFA and other fenamic acids could regulate mesenchymal stem cells’ (MSCs) lineage commitment and bone regeneration. Methods Here we treated two kinds of human MSCs with FFA at different concentrations in vitro and examined the effect of FFA on osteogenic differentiation of human MSCs. This was followed by heterotopic bone formation assay in nude mice. In addition, ovariectomized and aged mice were used as osteoporotic models to test the effect of FFA on osteoporosis. Besides, activators and inhibitor of nuclear factor-κB (NF-κB) signaling pathway and western blot were used to clarify the mechanism of the promoting effect of low concentration FFA on osteogenesis. Results Our results indicated that low concentrations of FFA could significantly enhance osteogenic differentiation of human MSCs in vitro, as well as in vivo. In addition, FFA treatment suppressed bone loss in ovariectomized and aged mice. Mechanistically, FFA at low concentrations promoted osteogenesis differentiation of human MSCs by inhibition of the NF-κB signaling pathway. Conclusions Collectively, our study suggested that low concentration FFA could be used in bone tissue engineering or osteoporosis by promoting osteogenic differentiation of human MSCs. Electronic supplementary material The online version of this article (10.1186/s13287-019-1321-y) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Low concentration flufenamic acid enhances osteogenic differentiation of mesenchymal stem cells and suppresses bone loss by inhibition of the NF-κB signaling pathway

Liu

Líu

et al. 2019

Stem Cell Res Ther

View full text Add to dashboard Cite

show abstract

“…13.3 h and up to 22 h [15]. According to these pharmacokinetic parameters, FFA might be an effective adjunctive antifungal agent when combined with FLU, AmB and CAS if administered at standard doses (normal dosage varies from 200 mg to 600 mg per day) [6]. Although systemic administration of FFA alone would not achieve levels that would be effective against Candida biofilms, high-dose FFA could also serve as a potential antifungal lock strategy for both prevention and treatment of catheter-related Candida biofilm infections.…”

Section: Discussionmentioning

confidence: 99%

“…FFA is a NSAID that has been specifically used to treat rheumatoid arthritis [6], although its potential as an antifungal agent has not been previously defined. We therefore sought to determine the effect of increasing concentrations of FFA, alone or in combination with standard concentrations of the commonly used antifungals amphotericin B (AmB), caspofungin (CAS) and fluconazole (FLU), for the prevention and treatment of C. albicans biofilms.…”

Section: Introductionmentioning

confidence: 99%

In vitro analysis of flufenamic acid activity against Candida albicans biofilms

Chavez-Dozal¹,

Jahng²,

Rane³

et al. 2014

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

In a recent high-throughput screen against specific Candida albicans drug targets, several compounds that exhibited non-specific antifungal activity were identified, including the non-steroidal anti-inflammatory drug flufenamic acid (FFA). This study sought to determine the effect of different doses of FFA, alone or in combination with fixed concentrations of the standard antifungal agents amphotericin B (AmB), caspofungin (CAS) or fluconazole (FLU), for the prevention and treatment of C. albicans biofilms. Biofilms were formed in a 96-well microplate followed by evaluation of antifungal activity using the XTT assay. FFA concentrations of ≥512 mg/L demonstrated >80% prevention of biofilm formation. FFA concentrations of 1024 mg/L demonstrated >85% reduction of mature biofilms. When FFA (≥8 mg/L) was used in combination with FLU (32 mg/L), antifungal activity increased to 99% for the prevention of biofilm formation. Similarly, when a FFA concentration of ≥8 mg/L was used in combination with either AmB (0.25 mg/L) or CAS (0.125 mg/L), antifungal activity also increased up to 99% for the prevention of biofilm formation. The inhibitory effect of FFA on C. albicans biofilms has not been reported previously, therefore these findings suggest that FFA in combination with traditional antifungals might be useful for the treatment and prevention of C. albicans biofilms.

show abstract

“…Furthermore, little is known about the effects of the fenamic acids on the differentiation of MSCs. FFA is a representative of the fenamic acids and has been used historically to treat a set of common diseases in the clinic [33,34]. FFA is easily obtained and is inexpensive.…”

Section: Stem Cells Internationalmentioning

confidence: 99%

Flufenamic Acid Inhibits Adipogenic Differentiation of Mesenchymal Stem Cells by Antagonizing the PI3K/AKT Signaling Pathway

Liu¹,

Li²,

Líu³

et al. 2020

Stem Cells International

View full text Add to dashboard Cite

Objectives. Flufenamic acid (FFA) is a representative of the fenamic acids, an important group of NSAIDs. In the present study, we study the effects of FFA on adipogenesis of human mesenchymal stem cells (MSCs) and we explore the potential mechanism. Methods. To investigate the effects of FFA on adipogenic differentiation of hMSCs, human adipose-derived stem cells (hASCs) and human bone marrow mesenchymal stem cells (hBMMSCs), representative of hMSCs, were treated with FFA during adipogenic differentiation in vitro. The effects of FFA in vivo were evaluated using a heterotopic adipose formation assay in nude mice as well as ovariectomized (OVX) and aged mice. To explore the mechanism of FFA, Western blot was used to determine activation of the PI3K/AKT signaling pathway. Results. Our results demonstrate that, at certain concentrations, FFA inhibited adipogenesis of human MSCs both in vitro and in vivo. Mechanistically, FFA inhibited adipogenesis of human MSCs by inhibiting the PI3K/AKT pathway. Conclusions. The present study indicated that FFA could be used to inhibit adipogenesis of human MSCs in tissue engineering and diseases related to excessive adipogenic differentiation of MSCs.

show abstract

Flufenamic acid in rheumatoid arthritis.

Cited by 15 publications

References 5 publications

Low concentration flufenamic acid enhances osteogenic differentiation of mesenchymal stem cells and suppresses bone loss by inhibition of the NF-κB signaling pathway

Low concentration flufenamic acid enhances osteogenic differentiation of mesenchymal stem cells and suppresses bone loss by inhibition of the NF-κB signaling pathway

In vitro analysis of flufenamic acid activity against Candida albicans biofilms

Flufenamic Acid Inhibits Adipogenic Differentiation of Mesenchymal Stem Cells by Antagonizing the PI3K/AKT Signaling Pathway

Contact Info

Product

Resources

About